<DOC>
	<DOCNO>NCT01212991</DOCNO>
	<brief_summary>The purpose study determine benefit enzalutamide versus placebo assess overall survival progression-free survival patient progressive metastatic prostate cancer fail androgen deprivation therapy yet receive chemotherapy .</brief_summary>
	<brief_title>A Safety Efficacy Study Oral MDV3100 Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Randomized , Double Blind Treatment Period : Histologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature Ongoing androgen deprivation therapy GnRH analogue bilateral orchiectomy Progressive disease despite androgen deprivation therapy define rise PSA level progressive soft tissue bony disease No prior treatment cytotoxic chemotherapy Asymptomatic mildly symptomatic prostate cancer Severe concurrent disease , infection , comorbidity , judgment Investigator , would make patient inappropriate enrollment Known suspect brain metastasis active leptomeningeal disease History another malignancy within previous 5 year curatively treat nonmelanomatous skin cancer OpenLabel Treatment Period : The follow inclusion criterion apply patient receive enzalutamide placebo doubleblind treatment . Eligible patient must meet inclusion criterion . Received randomized doubleblind treatment PREVAIL ; Openlabel day 1 visit within 6 month amendment approve becomes effective study site ; Is willing maintain androgen deprivation therapy gonadotropinreleasing hormone ( GnRH ) agonist/antagonist bilateral orchiectomy ; The exclusion criterion apply patient start new treatment enzalutamide receive placebo randomize treatment . Each patient must meet following criterion : Has take commercially available enzalutamide ( Xtandi ) ; Severe concurrent disease , infection , comorbidity , judgment Investigator , would make patient inappropriate enrollment Known suspect brain metastasis active leptomeningeal disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Progressive Metastatic Prostate Cancer</keyword>
</DOC>